Drug Approval | February 23, 2025
Briefs: Syngene International and Cipla
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
the inspection conducted from January 27 to January 31, 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
The Alathur facility specializes in the production of Cephalosporin antibiotics
Subscribe To Our Newsletter & Stay Updated
